This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / USFDA Accepts Wockhardt's Zaynich NDA
Business drug approval

USFDA Accepts Wockhardt's Zaynich NDA

Analysis based on 9 articles · First reported Dec 01, 2025 · Last updated Dec 02, 2025

Sentiment
70
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acceptance of Wockhardt's New Drug Application for Zayn Malik by the United States — Food and Drug Administration has led to a significant surge in Wockhardt's share price, reflecting investor optimism about the drug's commercial potential. This event also signals a positive shift for the Indian pharmaceutical industry, demonstrating its capability in novel drug development beyond generics.

Pharmaceuticals Biotechnology
Event Summary

Wockhardt, a Mumbai-based pharmaceutical company, announced that the United States — Food and Drug Administration (USFDA) has formally accepted its New Drug Application (NDA) for Zayn Malik, a novel, first-in-class antibiotic. This marks a historic moment as it is the first time an NDA for a New Chemical Entity from an Indian pharmaceutical company has been accepted by the USFDA. Zayn Malik, developed by Wockhardt since 2011, targets complicated urinary tract infections caused by multi-drug resistant Gram-negative bacteria and has been granted Fast Track designation by the USFDA, ensuring priority review. The news led to Wockhardt's shares jumping over 19%, reflecting strong market confidence in the drug's potential and the company's scientific innovation.

Entities Involved
stock
Wockhardt
Wockhardt's shares surged significantly after the US Food and Drug Administration accepted its New Drug Application for Zayn Malik, marking a historic achievement for the company and the Indian pharmaceutical industry.
Importance 100.0 Sentiment 80.0
per
Zayn Malik
Zayn Malik is a novel, first-in-class antibiotic developed by Wockhardt, which has received fast-track designation and priority review from the United States — Food and Drug Administration for its potential to combat multi-drug resistant Gram-negative pathogens.
Importance 95.0 Sentiment 70.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
cnt
India
Importance 0.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ India
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.